18β-Glycyrrhetinic acid induces human HaCaT keratinocytes apoptosis through ROS-mediated PI3K-Akt signaling pathway and ameliorates IMQ-induced psoriasis-like skin lesions in mice.
Animals
Apoptosis
/ drug effects
Cell Line
Cytokines
/ genetics
Female
Glycyrrhetinic Acid
/ analogs & derivatives
Humans
Imiquimod
Keratinocytes
/ drug effects
Mice, Inbred C57BL
Phosphatidylinositol 3-Kinases
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Psoriasis
/ chemically induced
Reactive Oxygen Species
/ metabolism
Signal Transduction
/ drug effects
Skin
/ drug effects
18β-Glycyrrhetinic acid
Apoptosis
PI3K-Akt signaling pathway
Psoriasis
ROS
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
03 06 2020
03 06 2020
Historique:
received:
09
04
2019
accepted:
26
05
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
10
4
2021
Statut:
epublish
Résumé
Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population worldwide. Hyperproliferative keratinocytes were thought to be an amplifier of inflammatory response, thereby sustaining persistence of psoriasis lesions. Agents with the ability to inhibit keratinocyte proliferation or induce apoptosis are potentially useful for psoriasis treatment. 18β-Glycyrrhetinic acid (GA), an active metabolite of glycyrrhizin, exhibits diverse pharmacological activities, including anti-inflammatory, anti-bacteria and anti-proliferation. The current study aims to evaluate the effects of GA on the proliferation and apoptosis of human HaCaT keratinocytes in vitro and investigate the effects of GA on the skin lesions of imiquimod (IMQ)-induced psoriasis-like mouse model in vivo. Cell viability was assayed by CCK-8. Flow cytometry was performed to measure apoptosis and reactive oxygen species (ROS), with Annexin V-FITC/PI detection kit and DCFH-DA probe respectively. Caspase 9/3 activities were measured using caspase activity assay kits. The protein levels of Akt and p-Akt were determined using Western blotting. IMQ was applied to induce psoriasis-like skin lesions in mice. The histological change in mouse skin lesions was detected using hematoxylin and eosin (H&E) staining. The severity of skin lesions was scored based on Psoriasis Area Severity Index (PASI). RT-PCR was employed to examine the relative expression of TNF-α, IL-22 and IL-17A in mouse skin lesions. GA decreased HaCaT keratinocytes viability and induced cell apoptosis in a dose-dependent manner. In the presence of GA, intracellular ROS levels were significantly elevated. NAC, a ROS inhibitor, attenuated GA-mediated HaCaT keratinocytes growth inhibition and apoptosis. In addition, GA treatment remarkably decreased p-Akt protein level, which could be restored partially when cells were co-treated with GA and NAC. LY294002 (a PI3K inhibitor) treatment significantly enhanced GA-mediated cytotoxicity. Moreover, GA ameliorated IMQ-induced psoriasis-like skin lesions in mice. GA inhibits proliferation and induces apoptosis in HaCaT keratinocytes through ROS-mediated inhibition of PI3K-Akt signaling pathway, and ameliorates IMQ-induced psoriasis-like skin lesions in mice.
Sections du résumé
BACKGROUND
Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population worldwide. Hyperproliferative keratinocytes were thought to be an amplifier of inflammatory response, thereby sustaining persistence of psoriasis lesions. Agents with the ability to inhibit keratinocyte proliferation or induce apoptosis are potentially useful for psoriasis treatment. 18β-Glycyrrhetinic acid (GA), an active metabolite of glycyrrhizin, exhibits diverse pharmacological activities, including anti-inflammatory, anti-bacteria and anti-proliferation. The current study aims to evaluate the effects of GA on the proliferation and apoptosis of human HaCaT keratinocytes in vitro and investigate the effects of GA on the skin lesions of imiquimod (IMQ)-induced psoriasis-like mouse model in vivo.
METHODS
Cell viability was assayed by CCK-8. Flow cytometry was performed to measure apoptosis and reactive oxygen species (ROS), with Annexin V-FITC/PI detection kit and DCFH-DA probe respectively. Caspase 9/3 activities were measured using caspase activity assay kits. The protein levels of Akt and p-Akt were determined using Western blotting. IMQ was applied to induce psoriasis-like skin lesions in mice. The histological change in mouse skin lesions was detected using hematoxylin and eosin (H&E) staining. The severity of skin lesions was scored based on Psoriasis Area Severity Index (PASI). RT-PCR was employed to examine the relative expression of TNF-α, IL-22 and IL-17A in mouse skin lesions.
RESULTS
GA decreased HaCaT keratinocytes viability and induced cell apoptosis in a dose-dependent manner. In the presence of GA, intracellular ROS levels were significantly elevated. NAC, a ROS inhibitor, attenuated GA-mediated HaCaT keratinocytes growth inhibition and apoptosis. In addition, GA treatment remarkably decreased p-Akt protein level, which could be restored partially when cells were co-treated with GA and NAC. LY294002 (a PI3K inhibitor) treatment significantly enhanced GA-mediated cytotoxicity. Moreover, GA ameliorated IMQ-induced psoriasis-like skin lesions in mice.
CONCLUSIONS
GA inhibits proliferation and induces apoptosis in HaCaT keratinocytes through ROS-mediated inhibition of PI3K-Akt signaling pathway, and ameliorates IMQ-induced psoriasis-like skin lesions in mice.
Identifiants
pubmed: 32493482
doi: 10.1186/s40360-020-00419-0
pii: 10.1186/s40360-020-00419-0
pmc: PMC7271483
doi:
Substances chimiques
Cytokines
0
Reactive Oxygen Species
0
18alpha-glycyrrhetinic acid
1449-05-4
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Imiquimod
P1QW714R7M
Glycyrrhetinic Acid
P540XA09DR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Subventions
Organisme : National Nature Science Foundation of China
ID : 31860314
Pays : International
Organisme : Natural Science Foundation of Guangxi Zhuang Autonomous Region
ID : 2018GXNSFAA281041
Pays : International
Organisme : Natural Science Foundation of Guangxi Zhuang Autonomous Region
ID : 2016GXNSFBA380146
Pays : International
Références
Int J Mol Med. 2009 Aug;24(2):189-96
pubmed: 19578792
Acta Derm Venereol. 2017 Oct 2;97(9):1087-1094
pubmed: 28597024
Eur J Pharmacol. 2016 Feb 5;772:144-51
pubmed: 26687635
J Agric Food Chem. 2009 Jan 28;57(2):754-61
pubmed: 19105645
PLoS One. 2014 Mar 07;9(3):e91146
pubmed: 24608112
Trends Immunol. 2009 May;30(5):201-8
pubmed: 19356981
Int J Mol Sci. 2019 May 24;20(10):
pubmed: 31137673
Cell Physiol Biochem. 2015;35(4):1335-46
pubmed: 25720416
PLoS One. 2013 Jun 25;8(6):e67078
pubmed: 23825622
N Engl J Med. 2007 Aug 16;357(7):682-90
pubmed: 17699818
Free Radic Biol Med. 2009 Oct 1;47(7):891-905
pubmed: 19577640
Eur J Pharmacol. 2011 Nov 30;670(2-3):399-408
pubmed: 21951963
Eur J Pharmacol. 2009 Jun 10;612(1-3):93-7
pubmed: 19361497
Sci Rep. 2016 May 05;6:25396
pubmed: 27145860
J Dermatol Sci. 2014 Jul;75(1):16-23
pubmed: 24726500
N Engl J Med. 2009 Jul 30;361(5):496-509
pubmed: 19641206
Int J Clin Exp Med. 2015 Sep 15;8(9):16266-72
pubmed: 26629143
Front Immunol. 2018 Jul 06;9:1549
pubmed: 30034395
Asian Pac J Cancer Prev. 2014;15(11):4405-9
pubmed: 24969860
Apoptosis. 2007 May;12(5):913-22
pubmed: 17453160
Oncol Rep. 2012 Dec;28(6):2069-76
pubmed: 22972479
Chem Biol Interact. 2019 Jan 25;298:112-120
pubmed: 30452899
Biomed Pharmacother. 2019 Feb;110:602-608
pubmed: 30537677
Acta Derm Venereol. 2014 Jul;94(4):371-9
pubmed: 24217655
Free Radic Biol Med. 1999 Sep;27(5-6):612-6
pubmed: 10490282
J Invest Dermatol. 2006 Dec;126(12):2565-75
pubmed: 17108903
Mar Drugs. 2018 Jan 25;16(2):
pubmed: 29370087
J Exp Med. 2006 Nov 27;203(12):2577-87
pubmed: 17074928
J Agric Food Chem. 2010 Aug 11;58(15):8623-9
pubmed: 20681651
Yonsei Med J. 2003 Dec 30;44(6):987-90
pubmed: 14703605
J Invest Dermatol. 2009 Jun;129(6):1339-50
pubmed: 19322214
PLoS One. 2014 Apr 02;9(4):e93690
pubmed: 24695790
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3669-78
pubmed: 25136095
J R Soc Interface. 2015 Feb 6;12(103):
pubmed: 25566881
J Immunol. 2005 Aug 15;175(4):2721-9
pubmed: 16081850
Food Chem Toxicol. 2019 Jul;129:365-375
pubmed: 31054998
Exp Dermatol. 2008 Jun;17(6):530-6
pubmed: 18218022
Pharm Dev Technol. 2009;14(1):80-9
pubmed: 18821270
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12646-51
pubmed: 15310853
Curr Drug Metab. 2010 Mar;11(3):210-27
pubmed: 20406192
Biochem Pharmacol. 2016 Apr 1;105:66-79
pubmed: 26850986
Mol Cell Biochem. 2016 Feb;413(1-2):87-95
pubmed: 26724949
Mini Rev Med Chem. 2003 Sep;3(6):540-56
pubmed: 12871157
Arch Dermatol Res. 2020 Jan;312(1):77-80
pubmed: 31367853
J Invest Dermatol. 2006 Feb;126(2):243-57
pubmed: 16418733
Antioxid Redox Signal. 2017 Jan 10;26(2):49-69
pubmed: 27393705
Nature. 2007 Feb 22;445(7130):866-73
pubmed: 17314973
J Ethnopharmacol. 2016 Jun 20;186:351-361
pubmed: 27041402
J Agric Food Chem. 2013 Feb 20;61(7):1509-20
pubmed: 23363008
J Cell Physiol. 2012 May;227(5):1923-31
pubmed: 21732363
Redox Rep. 2005;10(3):151-7
pubmed: 16156954
Acta Dermatovenerol Croat. 2009;17(3):182-6
pubmed: 19818217
Cell Death Dis. 2012 Jun 28;3:e334
pubmed: 22739986
J Immunol. 2006 Feb 1;176(3):1431-8
pubmed: 16424170
Drug Metab Rev. 2015 May;47(2):229-38
pubmed: 25825801
Antioxid Redox Signal. 2010 Sep 1;13(5):575-87
pubmed: 20367278
Int J Biochem Cell Biol. 2009 May;41(5):963-8
pubmed: 19027868
Diagn Pathol. 2014 May 29;9:102
pubmed: 24885087
Exp Dermatol. 2017 Apr;26(4):325-327
pubmed: 27943462
Life Sci. 2008 Sep 26;83(13-14):481-9
pubmed: 18721818
Curr Med Chem. 2016;23(12):1250-67
pubmed: 26997153
Nature. 2007 Feb 8;445(7128):648-51
pubmed: 17187052
Apoptosis. 2000 Nov;5(5):415-8
pubmed: 11256882
Phytother Res. 2008 Jun;22(6):709-24
pubmed: 18446848
Arch Dermatol Res. 2019 Mar;311(2):83-91
pubmed: 30483877
Nan Fang Yi Ke Da Xue Xue Bao. 2017 Nov 20;37(11):1512-1516
pubmed: 29180333
Cytokine. 2012 Oct;60(1):38-42
pubmed: 22840496
Int J Oncol. 2017 Aug;51(2):615-624
pubmed: 28656212
Antimicrob Agents Chemother. 2013 Jan;57(1):241-7
pubmed: 23114775
Mol Med Rep. 2014 Jun;9(6):2097-104
pubmed: 24718773
Curr Opin Neurobiol. 2001 Jun;11(3):297-305
pubmed: 11399427
J Invest Dermatol. 2003 Jan;120(1):48-55
pubmed: 12535197
PLoS One. 2015 Sep 18;10(9):e0138754
pubmed: 26382065
J Immunol. 2009 May 1;182(9):5836-45
pubmed: 19380832